U.S. patent number 3,717,708 [Application Number 04/770,424] was granted by the patent office on 1973-02-20 for blood coagulation complex.
This patent grant is currently assigned to Cutter Laboratories, Inc.. Invention is credited to Milton Michael Mozen, Shohachi Wada.
United States Patent |
3,717,708 |
Wada , et al. |
February 20, 1973 |
BLOOD COAGULATION COMPLEX
Abstract
A lyophilized mixture of coagulation components of human origin
useful in the treatment of patients, who bleed due to a congenital
or acquired deficiency of one or more of the coagulation Factors
II, VII, IX, X, prepared from human plasma collected in a citrate
anticoagulant, free of heparin, free of thrombin, free of the
activated form of Factor X, free of depressor activity, free of
anti-complement activity, and comprising the coagulation components
Factors II, VII, IX, X in essentially the same proportions as
normal human plasma and of a potency equivalent to a specific
activity of more than 0.5 clinical unit of each component per
milligram of protein; and the process of preparing such product by
selective adsorption and selective fractional elution.
Inventors: |
Wada; Shohachi (Oakland,
CA), Mozen; Milton Michael (Berkeley, CA) |
Assignee: |
Cutter Laboratories, Inc.
(Berkeley, CA)
|
Family
ID: |
25088488 |
Appl.
No.: |
04/770,424 |
Filed: |
October 24, 1968 |
Current U.S.
Class: |
530/384; 530/831;
514/802 |
Current CPC
Class: |
C12N
9/6429 (20130101); C12Y 304/21005 (20130101); Y10S
530/831 (20130101); Y10S 514/802 (20130101); A61K
38/00 (20130101) |
Current International
Class: |
C12N
9/74 (20060101); A61K 38/00 (20060101); A61k
025/00 () |
Field of
Search: |
;424/177 |
Other References
Chemical Abstracts, Vol. 66, entry 9221p, 1967 citing Steinbuch et
al., Probl. Gematol. Pereliv. Krovi 11(10), 15-21(1966) .
Lewis, Proc. Soc. for Experimental Biology and Medicine, Vol. 116,
No. 1, pages 120-122, May 1964 .
Voss, Hoppe-Seyler's Z. Physiol. Chem., Vol. 348, pages 1172-1178,
Sept. 1967 .
Biggs et al., Human Blood Coagulation and its Disorders, 3rd ed.,
published by Blackwell Scientific Publications, Oxford, 1962, pages
208, 210, 373, & 374 .
Prydz, J. Clin. & Lab. Investigation, Vol. 1, pages 101-107,
1964 .
Melin, Studies in the Application of Chromatographic Methods for
the Fractionation of the Proteins of Human Plasma, Harvard Univ.
April 1964, page 43.
|
Primary Examiner: Huff; Richard L.
Claims
What is claimed is:
1. A sterile lyophilized storage stable intravenous injectable
concentrate of citrated human plasma for controlling bleeding in
hemophilia, free of heparin, thrombin, the activated form of Factor
X, depressor activity and anticomplement activity, and containing
the coagulation Factors II, VII, IX, X in non-activated form, in
proportions substantially the same as in human plasma, and having a
Factor IX reconstituted potency of at least about 2,000 percent
that of normal plasma and a Factor IX specific activity of at least
about 0.5 clinical unit per milligram protein and a Factor IX
post-infusion biological half-life of about 20-50 hours.
2. A plasma concentrate according to claim 1 having a Factor IX
specific activity of at least about 0.9 clinical units per mg.
protein.
3. A mixture of a plasma concentrate according to claim 1 and a
NaCl-citrate electrolyte buffer.
4. A process for the production of a storage stable plasma
concentrate of the mixture of the Factors II, VII, IX and X
coagulation components of human plasma in non-activated form, free
of heparin, thrombin, the activated form of Factor X, depressor
activity and anticomplement activity, which comprises the steps of
applying Cohn Supernatant I, Method 6 from unmodified citrated
human plasma onto an ion exchange resin consisting essentially of
cross-linked dextran chains with diethylaminoethyl groups attached
by ether linkages to the glucose units of the polysaccharide
chains, and adsorbing thereon said coagulation components of the
plasma; selectively eluting the column with ammonium bicarbonate
solution of a pH of from about 7.3 to about 8.2 and increasing
molarity; separating the eluate fraction containing coagulation
components; freezing the separated eluate fraction and removing the
ammonium bicarbonate therefrom by lyophilizing the frozen
fraction.
5. The process of claim 4 wherein the ammonium bicarbonate solution
eluting the fraction containing the coagulation activity is about
0.75 M.
6. The process of claim 4 wherein the resin containing the adsorbed
coagulation components is washed free of ceruloplasmin with
ammonium bicarbonate solution of up to 0.3 molarity and the
coagulation components are eluted with ammonium bicarbonate
solution of about 0.75 M until the Factor IX is eluted.
7. The process according to claim 6 wherein the eluate fraction
containing coagulation activity is eluted at a pH of about 7.6-7.8.
Description
This invention relates to blood coagulation components and in
general has for its object the provision of a purified composition
of therapeutically useful blood coagulation components and to a
method for producing such components from readily available
materials.
There are estimated to be 100,000 cases of congenital hemophilia in
the United States. Of these, approximately 20,000 are cases of
hemophilia B, the blood of such patients being either totally
devoid of plasma thromboplastin component or seriously deficient in
plasma thromboplastin component. The disease therefore exists in
varying degrees of severity, requiring therapy anywhere from every
week up to once or twice a year. The completely deficient cases
require replacement therapy once every week; the partially
deficient cases require therapy only when bleeding episodes occur,
which may be as seldom as once a year. The bleeding episodes in
congenital, partially-deficient cases are generally caused by a
temporarily acquired susceptibility rather than by injury alone.
Intravenous injection of a sufficiently large amount of fresh
plasma, or an equivalent amount of fresh blood, temporarily
corrects the defect of a deficient subject. The beneficial effect
often lasts for two or three weeks, although the coagulation defect
as measured by in-vitro tests on the patient's blood appears
improved for only two or three days. Such therapy with fresh plasma
or fresh blood is effective but it has several serious drawbacks:
(1) it requires ready availability of a large amount of fresh
plasma; (2) requires hospitalization for the administration of the
plasma; (3) a great many of the patients become sensitized to
repeated blood or plasma infusions and ultimately encounter fatal
transfusion reactions; (4) at best plasma can only partially
alleviate the deficiency; and (5) prolonged treatment or surgery is
not possible because the large amounts of blood or plasma which are
required will cause acute and fatal edema.
Several investigators noted that the mixing of blood of certain
hemophilic patients would result in the mutual correction of the
clotting defect of each blood. Interpretation of these findings was
eventually made by Aggeler and co-workers [Proc. Soc. Exptl. Biol.
Med. 79:692-696 (1952)] and S. G. White et al [Blood 8:101-124
(1953)]. These workers, studying a male patient with a severe
hemorrahagic diathesis associated with a prolonged clotting time
which was clinically indistinguishable from classic hemophilia,
postulated the existence of a new clotting factor. Aggeler et al,
recognizing that the new factor was a precursor of thromboplastin,
named it Plasma Thromboplastin Component (PTC). The work was
confirmed by Biggs et al. [Brit. Med. J. 2:1378-1382 (1952)] in
England, who gave it the name Christmas Factor, and by Soulier and
Larrieu [New Eng. J. Med. 249:547-553 (1953)] in France, who called
it Antihemophilic Factor B. This factor is now officially
designated Factor IX. The role played by Factor IX, as well as by
Factors II, VII and X, is illustrated by the following simplified
diagram of the coagulation process. ##SPC1##
In collaboration with Aggeler et al., the first fractionated PTC
preparation was prepared [Revue d'Hematologie 9:447-453 (1954)].
The PTC was absorbed on barium sulfate from a solution of Cohn
Fraction IV and eluted with 0.34 M sodium citrate. The yields are
very small, and the post-infusion in-vivo activity was only about
one-fourth that predicted from in-vitro assays by a prothrombin
consumption test.
Later, in collaboration with Aggeler et al., a process was
developed by which PTC was adsorbed onto barium sulfate from EDTA
anticoagulated plasma, eluted with a sodium chloride-sodium citrate
buffer, and further purified by cold ethanol fractionation. This
preparation was used clinically with excellent results [Aggeler, P.
M. et al. Trans. 6the Congress, Internat. Soc. Hematol. Grune &
Stratton, N. Y., pgs. 490-497 (1958)]. The process was later
published in detail, and it was pointed out that the process was
never commercialized because the Albumin and Plasma Protein
Fraction obtained as by-products were contaminated with potentially
hazardous levels of barium [Hink, J. H. and Johnson, F. F., The
Hemophilias, CH. 18, page 156, edited by Brinkhous, Univ. Of North
Carolina Press (1964)]. Biggs et al. in England [Brit. J. Haematol.
7:349-364 (1961)] and Janiak and Soulier [Thromb. et Diath.
Haemorr. 8:406-424 (1962)] in France later prepared Factor IX by a
similar process, substituting tricalcium phosphate for the barium
sulfate. However, spontaneous formation of thrombin always occurred
and it was always necessary to add heparin, both during and after
processing to neutralize the potentially dangerous thrombin.
Tullis et al. [New Eng. J. Med. 273:667-674 (1965)] have prepared
and studied a somewhat similar plasma fraction, which they refer to
as "prothrombin complex". In the Tullis process, the blood was
collected through a calcium-removing ion exchange resin, and the
resulting resin-plasma adsorbed onto DEAE cellulose. Elution was
accomplished with a sodium phosphate-sodium chloride buffer
stabilized with EDTA. Clinical studies on the "prothrombin complex"
are described in the reference, but other data characterizing the
complex are not available.
The preponderance of blood generally taken and available for
transfusion is protected from coagulation by treatment with a
citrate anticoagulant which allows the blood to be utilized for
only a limited period of time. After this limited time expires,
this blood must be discarded or it can be made available for
fractionation into certain useful components. As a matter of fact,
the major source of whole blood converted to plasma for
fractionation comes from outdated blood which has been protected by
citrate anticoagulation. It is, therefore, important that processes
for the fractionation of plasma, such as to obtain a Factor IX
containing concentrate, be directed to citrate preserved blood. An
object of this invention is that the process for making the
concentrate of this invention starts with plasma taken from citrate
preserved blood.
It is also important that such concentrates do not contain thrombin
since the injection of thrombin into a human would be considered
highly dangerous. Although it is possible to neutralize thrombin
activity with heparin, it would be preferable not to have the
thrombin there in the first place. Heparin is undesirable in a
Factor IX containing concentrate because it also is potentially
hazardous to the patient and because it causes difficulties in
assaying the coagulation factors in the concentrate. In the
administration of a Factor IX containing concentrate, constant
monitoring of the patient's coagulation status is required, and the
presence of heparin will not only complicate this testing
procedure, but will make the results thus obtained unreliable. An
object of this invention is that the concentrate be free of both
thrombin and of heparin.
It is a further object of this invention to provide a concentrate
that comprises coagulation components II, VII, IX and X in
proportions essentially equal to those found in plasma, yet free of
the activated form of Factor X, thereby reducing the danger of
precipitating intravascular coagulation.
It is a further object of this invention to provide a concentrate
free of the anticomplement activity which is so often associated
with plasma globulins and which would make the intravenous
administration of the product highly dangerous.
It is a further object of this invention to provide a very pure
product by selective adsorption of active components and further
selectivity by fractional elution.
Other objects and advantages of the invention will appear from the
following description of preferred embodiments thereof.
Details of Making Product
Very generally, the product is made by starting from Effluent I,
prepared by the Cohn Method 6. The complex of Factors II, VII, IX,
X is adsorbed onto DEAE Sephadex, which is an anion exchanger,
diethylaminoethyl Sephadex, consisting of cross-linked dextran
chains with diethylaminoethyl groups attached by ether linkages to
the glucose units of the polysaccharide chains, supplied by
Pharmacia Fine Chemicals, Inc., Piscataway, New Market, N. J. The
spent Effluent I is returned to the plasma fractionation process so
that none of the other plasma components are wasted. The DEAE
Sephadex is fractionally eluted with increasing concentrations of
ammonium bicarbonate solution. The complex of the invention is
eluted in the fraction between 0.3 M and 0.75 M ammonium
bicarbonate at pH 7.3-8.2.
More specifically, the preferred procedure is as follows:
A. Adsorb the Effluent I of the standard plasma fractionation
process onto a column of freshly equilibrated DEAE Sephadex in an
amount of 10 Gms. (wet weight) per liter of Effluent I, at
0.degree. to -3.degree.C. Return the spent Effluent I to the plasma
fractionation process just prior to precipitation of Fraction
II+III. B. Wash the DEAE Sephadex column with 0.2 M ammonium
bicarbonate at pH 7.0-7.8 until no further protein is eluted and
discard the wash.
C. In the same manner, wash the DEAE Sephadex column with 0.3 M
ammonium bicarbonate, at pH 7.0-7.8 until no further protein is
eluted; the blue ceruloplasmin is eluted with this wash; discard
the wash.
D. In the same manner, elute the DEAE Sephadex column with 0.75 M
ammonium bicarbonate, at pH 7.6-7.8 until the Factor IX is
eluted.
E. Freeze and lyophilize the eluate of step D; the ammonium
bicarbonate sublimes leaving a salt-free protein powder equivalent
to about 350 mg. per liter of Effluent I; assay for Factor IX, and
store in a moisture-proof container at 5.degree.c or below.
A modification of the product of this invention is the product in
an electrolyte buffer suitable for intravenous administration as
follows:
F. Slowly dissolve the dry protein powder in a diluent of 0.05 M
sodium citrate and 0.088 M sodium chloride to result in a final
concentration of 25 units of Factor IX per ml.; as the powder
dissolves, maintain the pH at 7.0-7.5 by additions of 1 N sodium
hydroxide; adjust the final pH to 7.3 .+-. 0.1.
G. Sterilize by filtration through a sterile 0.2 micron porosity
membrane filter.
H. Aseptically fill convenient portions into sterile bottles,
freeze, and lyophilize. Store at 5.degree.C.
I. For human administration, the content of the vial in step H is
aseptically redissolved in water for injection. Alternatively, the
product of step D can be sterile filled and lyophilized to a
salt-free product. In this instance it is reconstituted with a
suitable isotonic diluent prior to human injection.
The above process recites the details which are preferred at this
time. However, many variations can be made without departing from
the general principles of the invention.
For example, the amount of DEAE Sephadex relative to the volume of
Effluent I may be varied over a wide range. The use of larger
amounts of DEAE Sephadex will result in a lower degree of purity
and greater yield of the coagulation complex, and a greater loss of
other plasma proteins normally recoverable in subsequent steps. The
use of smaller amounts of DEAE Sephadex will result in even higher
degrees of purity, but will also result in considerably lower
yields. Although DEAE Sephadex is the preferred anionic exchanger,
presumably other anionic adsorbents would work also.
The elution step with ammonium bicarbonate is extremely important
to the invention of this process. The unique selectivity obtained
by application of the ammonium bicarbonate salt gradient elution
combined with the unique volatility factor of ammonium bicarbonate
are very important aspects of this process for the following
reasons:
1. Ammonium bicarbonate being a volatile, inorganic salt is
completely removed from the desiccated product thus resulting in a
completely salt-free protein preparation. This offers an advantage
in that the final clinical preparation may be easily adjusted to
isotonicity.
2. The recovery of a salt-free protein obviates the necessity of
extensive salt removal procedures such as dialysis, gel filtration,
ultra filtration, etc., thus a commercially feasible large scale
operation becomes more practical.
3. Ammonium bicarbonate was found to offer selectivity in the
elution of the bound proteins, allowing the ready separation of
undesirable impurities such as ceruloplasmin. As a result, the
desired components are eluted in a higher state of purity than can
be accomplished with conventional eluting solutions.
The above specified pH ranges for the elution steps are preferred,
although higher pHs up to 8.2 could be employed, the higher pHs
contributed to instability of the product.
These conditions have been designed to make further fractionation
of the spent Effluent I more practical or possible.
The dissolving of the dried protein, its concentration, the nature
of the electrolyte buffer, and the filtration are all standard
steps which can be varied by anyone familiar with the art.
CHARACTER OF PRODUCT
The product resulting from the above described process is a
lyophilized product containing human Factors II, VII, IX and X in a
suitable electrolyte buffer such as sodium chloride-sodium citrate
buffer. The product is free of thrombin, thromboplastin activity,
anticomplement activity, and depressor activity. It has a specific
activity of at least about 0.5 Factor IX unit per mg. protein. One
Factor IX unit is defined as that amount of Factor IX activity
contained in one ml. of fresh average pooled plasma. Assay results
are expressed in terms of a lyophilized reference standard which
contains 0.7 unit per ml. upon reconstitution.
ASSAYS
In-Vito Assay of Factor IX Activity
The assay was based on the partial thromboplastin time technic of
Langdell, Wagner, and Brinkhous [J. Lab. Clin. Med. 41:637-647
(1953)] and the kaolin clotting time method of Proctor and Rapaport
[Am. J. Clin. Path. 36:212-219 (1961)] . Platelet Factor 3 was
supplied by a cephalin suspension. Maximum surface contact
activation was achieved with a Celite powder. All other clotting
factors (except Factor IX) were supplied by a substrate comprising
plasma from a patient severely deficient in Factor IX mixed with
barium sulfate adsorbed beef plasma. Quantitation of an unknown
specimen was made by comparing its clotting time in the test with
that achieved by dilutions of a normal standard.
REAGENTS
1. calcium Chloride Solution. 0.05 M CaCl.sub.2
2. Veronal Buffer
2.94 gm Sodium Barbital
3.67 gm. Sodium Chloride
105 ml. 0.1 N Hydrochloric Acid
q.s. 500 ml. with distilled water
3. Celite. Analytical Filter Aid, Johns Manville.
4. Cephalin Suspension. Prepared from rabbit brain thromboplastin
according to Bell and Alton [Nature 174:880-881 (1954)] .
470.sup.
5. Cephalin-Celite Reagent. Equal volumes of Cephalin Suspension
diluted 1:50 in Veronal buffer at pH 7.3 .+-. 0.1, and Celite, 1.0
gm. suspended in 5 ml. 0.9 percent NaCl solution were mixed.
6. Diluting Fluid I (DF I)
50 ml. 0.1 M Sodium Citrate
300 ml. 0.15 M Sodium Chloride
7. Diluting Fluid II (DF II)
20 ml. Veronal Buffer
60 ml. 0.15 M NaCl
8. Barium Sulfated Beef Plasma. Oxalated beef plasma was adsorbed
with 100 mg./ml. barium sulfate and stored in small aliquots at
-20.degree.C.
9. substrate Plasma
1 part citrated plasma from a patient severely deficient in Factor
IX (stored in small aliquots at -20.degree.C.) was mixed with 3
parts barium sulfated beef plasma.
10. Reference Standard
Lyophilized plasma reference standard No. 788-27.
Assigned potency = 0.7 unit per ml. ratio 37.degree. al 97
(1955)]
The cephalin-celite reagent was thoroughly re-suspended before use.
The substrate reagents were thawed with constant agitation in a
water bath at 37.degree.C, then mixed in a ratio of one part
patient's plasma to three parts BaSO.sub.4 beef plasma. It was then
kept in a melting ice bath with all other reagents except the
calcium solution, which was placed in a 37+C water bath. A standard
reference plasma was diluted 1/10, 1/50, 1/100, etc., with diluting
fluids I and II, according to the method Hjort, et al. [J. Lab.
Clin. Med. 46:89-97 (1955)]. Unknowns were tested at suitable
dilutions. One-tenth ml. of re-suspended cephalin-celite, 0.1 ml.
of substrate plasma, and 0.1 ml. of diluted unknown or standard
plasma were transferred to a glass tube in the 37.degree.C water
bath and a stopwatch started. The mixture was gently tilted during
the three minute incubation period to keep the celite in
suspension. At the end of three minutes, 0.1 ml. of the CaCl.sub.2
solution was added and a second stopwatch started. The tube was
tilted until clotting occurred. All tests were done in duplicate
and the clotting times averaged.
The standard reference plasma was tested with each set of unknowns.
A graph was constructed on log-log paper with clotting time on the
ordinate and plasma concentrations on the abscissa. The clotting
times of the various dilutions of the standard reference plasma
were plotted, and the best possible line drawn through the points.
The Factor IX concentrations of unknown specimens were determined
by reference to this graph. The values obtained for the various
concentrations of the unknown were averaged.
In-Vitro Assay of Factor II (Prothrombin)
The Factor II assay was a typical Owren One-Stage assay. The
results are expressed as units per ml., one unit of prothrombin
being defined as that prothrombin activity contained in one ml. of
a frozen plasma standard.
In-Vitro Assay of Thromboplastin and Thrombin
Thromboplastin and thrombin were estimated simultaneously, by a
typical recalcification time test. The clotting time in seconds was
compared for the sample and for a control, as follows:
Sample 0.1 ml. sample (at various dilutions 0.1 ml. citrated plasma
0.1 ml. 0.05 M CaCl.sub.2 Control 0.1 ml. 0.15 M NaCl 0.1 ml.
citrated plasma 0.1 ml. 0.05 M CaCl.sub.2
The "sample" was tested at various dilutions with distilled water
because high concentrations of neutral electrolyte will inhibit
clotting due to any thromboplastin or thrombin.
ASSAY FOR ANTI-COMPLEMENT ACTIVITY
The anti-complement assay was done as follows:
Reagents:
1. CF Saline
Stock Ca-Mg solution
10 g. CaCl.sub.2 q.s. 100 ml. with distilled water. 4 g.
MgCl.sub.2
Add 1 ml. stock solution of 1 liter 0.85% NaCl
2. Alsever's Solution
20.5 g. Dextrose 4.2 g. NaCl 9.5.1 liter with 8.0 g. Na Citrate
distilled water. 0.55 g. Citric Acid
3. Sheep Red Blood Cells (S-RBC)
Approximately 20 ml. cells were drawn into 40 ml. Alsever's
solution. For assay, a portion of cells were washed 3 times with
normal saline, then a 2 percent suspension was prepared with CF
saline as diluent.
4. Hemolysin
Stock solution 1:100 was prepared using phenol as preservative.
5. Complement
Reconstituted as per directions with supplied diluent.
6. Sensitized RBC
Warmed 15-30 minutes at 37.degree.C before use.
2 units/0.2 ml. vol. Hemolysin equal volume 2% S-RBC
Titration
1. Hemolysin
Doubling dilutions through 1:32 of stock 1:100 solution using CF
saline as diluent.
0.2 ml. hemolysin dilutions 0.2 ml. Complement (1:30 with CF
saline) Incubated 30 0.2 ml. 2% RBC min. at 37.degree.C 0.5 ml. CF
saline
Highest dilution of hemolysin giving complete lysis = 1 unit.
Amount used in assay = 2 units/0.2 ml. vol.
Controls (incubated 30 min. at 37.degree.C)
(1) 0.2 ml. hemolysin (undiluted) 0.2 ml. 2% RBC 0.7 ml. CF saline
All Controls should be (2) 0.2 ml. complement (1:30) negative (no
lysis) 0.2 ml. 2% RBC 0.7 ml. CF saline (3) 0.2 ml. 2% RBC 0.9 ml.
CF saline
2. Complement
Tube No. 1 2 3 4 5 6 7 8 Complement 1:30 ml. .12 .11 .10 .09 .08
.07 .06 .05 CF saline (ml.) .48 .49 .50 .51 .52 .53 .54 .55
Incubate dilutions 30 min. at 37.degree.C
Add 0.4 ml. sensitized RBC to each.
Incubate 30 min. at 37.degree.C
Least amount C' giving complete lysis = "exact" unit.
Next highest amount = "full" unit
Amount used in assay = 2 "full" units/0.2 ml. vol.
Control (incubated 30 min. at 37.degree.C)
0.4 ml. sensitized RBC Should be negative 0.6 ml. CF saline (no
lysis)
Test:
0.2 ml. Sample (doubling dilutions with CF saline as diluent)
0.2 ml. CF saline
0.2 ml. C' (2 units)
Dilutions were incubated 1 hour at 37.degree.C
0.4 ml. sensitized RBC was added to each.
Incubated 30 min. at 37.degree.C
End point = highest dilution sample showing at least 50 percent
lysis.
Controls (incubated 30 min. at 37.degree.C)
(1) 0.2 ml. sample (lowest dilution used) Should be negative 0.4
ml. sensitized RBC (no lysis) 0.4 ml. CF saline (2) 0.2 ml. C' (2
units) Should be negative 0.4 ml. sensitized RBC (no lysis) 0.4 ml.
CF saline (3) 0.4 ml. sensitized RBC Should be negative 0.6 ml CF
saline (no lysis)
Depressor Activity
The depressor activity was measured by the Depressor Substances
Test described in the USP XVII, page 843.
The results obtained by these various techniques are set forth in
Table I.
TABLE I
TEST * RESULTS Lot No.: A B C D
__________________________________________________________________________
Factor IX 480.sup. a 540.sup. a 500.sup. a 550.sup. a Factor II
700.sup. a 640.sup. a 510.sup. a 370.sup. a Factor VII 380.sup. a
500.sup. a 480.sup. a 570.sup. a Factor X 1100.sup. a 500.sup. a
670.sup. a 570.sup. a Protein 962.sup. b 606.sup. b 484.sup. b
340.sup. b Specific Activity 0.5 0.89 1.03 1.6 pH 6.9 6.8 6.8 7.2
Na.sup.+ 242.sup. c 237.sup. c 240.sup. c 237.sup. c Cl.sup.-
90.sup. c 94.sup. c 88.sup. c 87.1.sup. c Citrate (C.sub.6 H.sub.5
O.sub.7).tbd. 51.sup. c 48.sup. c 51.sup. c 50.2.sup. c
Thrombin-Thromboplastin none none none none Depressor Substances
pass pass pass pass *Expressed as values per vial, or as per unit
volume when reconstituted with 20 ml. .sup.a -- units .sup.b -- mg.
.sup.c -- Eq./L.
a batch of coagulation complex of this invention was prepared
according to the process described herein. Tests showed the lot to
be free of depressor activity, thrombin and thromboplastin, and
anticomplement activity. The batch was stored lyophilized at
ambient temperature and re-tested 3 months and 6 months later. No
depressor activity, thrombin, or thromboplastin were found.
To demonstrate the stability of the complex of this invention, a
large number of bottles from each of three lots were placed at
three different temperature stations and assayed at appropriate
intervals. Stability data on lot PR 2240 (1.8 percent moisture),
after reconstituting each bottle with 20 ml. water, is presented as
an example in Table II.
TABLE II
Elapsed Units Factor IX per ml. Assay Date Time 5.degree.C. Room
Temp. 40.degree.C. 2/9/68 initial 33.6 33.6 33.6 3/19/68 5 weeks
34.6 4/19/68 9 weeks 35.4 29.0 5/9/68 3 months 28.0 5/20/68 31/2
months 28.7 6/19/68 4 months 34.2 32.6 32.6 7/22/68 5 months 21.8
8/8/68 6 months 35.0
The potency of the complex of this invention was demonstrated by
reconstituting a portion of a batch prepared according to the
process described herein and assaying it for clotting factors. The
results, expressed as percent of normal plasma are shown in Table
III.
TABLE III
II 2550% VII 2400% IX 2500% X 2350% (Specific activity of Factor
IX: 1.03 units/mg. protein)
The complex of this invention was tested for and passed all
requirements of this USP XVII assay for depressor substances. The
results are shown in Table IV.
table iv
change in Mean Arterial Dose Pressure 0.05 mcg/Kg. Histamine* i.v.
-35 0.10 mcg/Kg. Histamine* i.v. -50 0.15 mcg/Kg. Histamine* i.v.
-55 0.10 mcg/Kg. Histamine* i.v. -50 0.10 mcg/Kg. Histamine* i.v.
-50 Invention sample 0.2 cc/Kg. i.v. -5 0.10 mcg/Kg. Histamine*
i.v. -40 Invention sample 0.2 cc/Kg. i.v. -5 0.10 mcg/Kg.
Histamine* i.v. -40 (Invention sample diluted to 3.0 cc) *(Free
Base)
The thromboplastin-thrombin assay above described gave the
following results when a sample of the complex of this invention
was tested:
TABLE V
Sample tested Clotting time (secs.) Saline (control) 135 Invention
sample undiluted 180 Invention sample diluted 1:3 135 Invention
sample diluted 1:10 135
The failure of invention sample to enhance the clotting time of
normal human plasma is evidence of the absence of thrombin,
thromboplastin substances, and the activated form of Factor X.
CLINICAL RESULTS
Human assays have been conducted with the coagulation complex of
this invention with patients deficient in Factor IX and with
patients deficient in Factor VII. The coagulation data from one of
these human assays in a Factor IX deficient patient are presented
in Tables VI and VII. During 48 hours subsequent to the
administration of the product of this invention containing 2,030
units of Factor IX, there were no abnormalities in blood pressure,
pulse, temperature, and respiration. Furthermore, two
administrations of the coagulation complex of this invention to the
same patient 13 days apart gave no evidence of sensitization or
antigenicity. ##SPC2##
The post-infusion disappearance curve of Factor IX is shown on the
following page. The curve is typically bi-phasic; T 1/2 of the
first component is 71/2 hours; T 1/2 of the second component is 47
hours. The post-infusion half life of the Factor IX in different
patients appears to vary from about 20 hours to about 50 hours.
##SPC3##
Reliable coagulation assays have been collected for the four
coagulation components following administration of eight different
lots to each of two or more patients. In those patients who would
be considered fairly normal (including bleeding patients, but
excluding those exhibiting fibrinolysis or widely shifting plasma
volumes), the administration of one unit per pound of body weight
results in approximately a 4 per cent rise in Factors II, VII, IX,
and X. The post-infusion rise of Factor X is generally a little
higher than that of the other three factors.
The product of this invention has been used by 14 clinical
investigators in the treatment of emergency situations involving
over 65 patients. These are patients who had either a permanent
congenital deficiency of either Factor VII or IX or X, or who had a
temporary acquired deficiency of all four factors (II, VII, IX and
X); and who were either highly reactive to plasma or could not
tolerate the volume of plasma which would be required; and who were
either suffering a serious bleeding episode or who required
protection while undergoing major emergency surgery.
The mode of administering the product of this invention will be
readily known by physicians. Very generally the lyophilized product
is reconstituted with water for injection to make an isotonic
solution which is injected intravenously to the patient.
The disclosures and description herein are purely illustrative and
are not intended to be in any sense limiting to change that might
suggest themselves to those skilled in the art without departing
from the spirit and scope of the invention.
* * * * *